News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
301,048 Results
Type
Article (16150)
Company Profile (261)
Press Release (284630)
Multimedia
Podcasts (129)
Webinars (13)
Section
Business (91265)
Career Advice (207)
Deals (13580)
Drug Delivery (72)
Drug Development (51230)
Employer Resources (34)
FDA (6056)
Job Trends (5279)
News (146581)
Policy (10146)
Tag
2025 Best Places to Work (13)
2026 Best Places to Work (19)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Standard (2)
2027 Genetown Elite (1)
2027 Genetown Standard (4)
2027 Pharm Country Standard (3)
40 Under 40 (4)
Academia (1002)
Accelerated approval (39)
ADA (34)
Adcomms (16)
Allergies (128)
Alliances (21863)
ALS (204)
Alzheimer's disease (1275)
Antibody-drug conjugate (ADC) (583)
Approvals (6486)
Artificial intelligence (506)
ASCO (225)
Autoimmune disease (411)
Automation (21)
Bankruptcy (115)
Belgium (29)
Best Places to Work (4607)
BIO (56)
Biologics (71)
BIOSECURE Act (7)
Biosimilars (163)
BioSpace Insights (83)
Biotechnology (179)
Bispecific (53)
Bladder cancer (143)
Brain cancer (74)
Breast cancer (511)
Cancer (5064)
Cardiovascular disease (376)
Career advice (204)
Career pathing (16)
CAR-T (347)
CDC (12)
CDMO (127)
Celiac Disease (4)
Cell therapy (889)
Cervical cancer (31)
Clinical research (46724)
Collaboration (1789)
Commercialization (44)
Company closure (4)
Compensation (985)
Complete response letters (74)
COVID-19 (1168)
CRISPR (131)
CRO (4)
C-suite (1057)
Cystic fibrosis (132)
Data (7656)
Denatured (27)
Depression (135)
Dermatology (131)
Diabetes (408)
Diagnostics (1599)
Digital health (21)
Diversity (6)
Diversity, equity & inclusion (11)
Drug discovery (365)
Drug pricing (57)
Drug shortages (4)
Duchenne muscular dystrophy (343)
Earnings (34068)
Editorial (39)
Employer branding (4)
Employer resources (32)
ESMO (312)
Events (55896)
Executive appointments (805)
Eye disease (16)
FDA (8884)
Fibrodysplasia Ossificans Progressiva (11)
Fragile X (6)
Friedreich's ataxia (28)
Frontotemporal dementia (36)
Funding (1503)
Gene editing (264)
Generative AI (51)
Gene therapy (727)
GLP-1 (642)
Government (1230)
Grass and pollen (3)
Guidances (182)
Healthcare (6916)
Hematology (143)
HIV (42)
Huntington's disease (76)
Idiopathic pulmonary fibrosis (10)
IgA nephropathy (125)
Immunology and inflammation (295)
Immuno-oncology (122)
Indications (192)
Infectious disease (1351)
Inflammatory bowel disease (216)
Inflation Reduction Act (10)
Influenza (64)
Intellectual property (263)
Interviews (30)
IPO (7447)
IRA (13)
Job creations (879)
Job search strategy (159)
JPM (41)
Kidney cancer (13)
Kidney disease (125)
Labor market (46)
Layoffs (281)
Leadership (22)
Legal (1416)
Licensing (99)
Liver cancer (55)
Longevity (39)
Lung cancer (701)
Lung diease (19)
Lymphoma (369)
Machine learning (40)
Management (8)
Manufacturing (722)
Marketing (25)
MASH (188)
Medical affairs (4)
Medical device (2831)
Medtech (2889)
Melanoma (110)
Mergers & acquisitions (7016)
Metabolic disorders (1122)
Middle East (1)
mRNA (231)
Multiple sclerosis (164)
Multispecific (6)
NASH (14)
Netherlands (19)
Neurodegenerative disease (433)
Neuropsychiatric disorders (105)
Neuroscience (2798)
Neurotech (2)
NextGen: Class of 2026 (2088)
Non-profit (921)
Now hiring (50)
Obesity (501)
Opinion (165)
Ovarian cancer (234)
Pain (174)
Pancreatic cancer (311)
Parkinson's disease (366)
Partnered (21)
Patents (512)
Patient advocacy (7)
Patient recruitment (683)
Patient selection (93)
Peanut (55)
People (28080)
Peptides (34)
Pharmaceutical (31)
Pharmacy benefit managers (9)
Phase 1 (16533)
Phase 2 (21744)
Phase 3 (13761)
Pipeline (9264)
Policy (116)
Postmarket research (854)
Preclinical (6995)
Press Release (30)
Prostate cancer (248)
Psychedelics (89)
Radioligand (3)
Radiopharmaceuticals (343)
Rare diseases (1136)
Real estate (1470)
Recruiting (12)
Regenerative medicine (24)
Regulatory (11505)
Reports (33)
Research institute (1026)
Resumes & cover letters (28)
Rett syndrome (51)
RNA editing (38)
RSV (26)
Schizophrenia (177)
Series A (298)
Series B (198)
Series C (1)
Service/supplier (1)
Sickle cell disease (110)
Special edition (24)
Spinal muscular atrophy (131)
Sponsored (23)
Startups (2064)
State (1)
Stem cells (7)
Stomach cancer (7)
Substance use disorders (20)
Supply chain (49)
Switzerland (14)
Tariffs (20)
The Weekly (100)
Vaccines (476)
Venture capital (121)
Weight loss (265)
Wet AMD (6)
Women's health (64)
Women in leadership (1)
Worklife (4)
Date
Today (86)
Last 7 days (471)
Last 30 days (2280)
Last 365 days (18581)
2026 (16950)
2025 (18160)
2024 (20533)
2023 (22472)
2022 (27493)
2021 (28884)
2020 (24221)
2019 (16460)
2018 (11942)
2017 (13896)
2016 (11964)
2015 (14483)
2014 (10504)
2013 (7583)
2012 (7593)
2011 (7698)
2010 (7472)
Location
Africa (165)
Alabama (86)
Alaska (2)
Arizona (108)
Arkansas (6)
Asia (19432)
Australia (3344)
California (10514)
Canada (2600)
China (1387)
Colorado (397)
Connecticut (396)
Delaware (364)
Europe (41719)
Florida (1387)
Georgia (291)
Hawaii (3)
Idaho (19)
Illinois (657)
India (78)
Indiana (249)
Iowa (13)
Japan (408)
Kansas (94)
Kentucky (13)
Louisiana (18)
Maine (14)
Maryland (1074)
Massachusetts (8378)
Michigan (146)
Minnesota (362)
Mississippi (4)
Missouri (41)
Montana (17)
Nebraska (6)
Nevada (71)
New Hampshire (22)
New Jersey (2364)
New Mexico (15)
New York (2555)
North Carolina (1215)
North Dakota (9)
Northern California (5472)
Ohio (255)
Oklahoma (13)
Oregon (28)
Pennsylvania (1902)
Puerto Rico (12)
Rhode Island (31)
South America (223)
South Carolina (20)
Southern California (4260)
Tennessee (73)
Texas (1510)
United States (34640)
Utah (145)
Virginia (215)
Washington D.C. (37)
Washington State (852)
West Virginia (1)
Wisconsin (82)
Wyoming (1)
301,048 Results for "tune therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
IDBS and a-tune strengthen long-standing partnership to connect Preclinical workflows
October 29, 2026
·
4 min read
Press Releases
Tune Therapeutics Announces Late-Breaking Oral Presentation for TUNE-401 at European Association for the Study of the Liver Congress 2026
May 5, 2026
·
2 min read
Press Releases
Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026
June 1, 2026
·
5 min read
Press Releases
NRDL+ Releases 2026 Mid-Year China Access Outlook as China Fine-Tunes Innovation Access Under Tighter Constraints
Executive strategic briefing examines how China’s evolving health policy, coverage, and financing environment is reshaping decisions across the medical technology lifecycle tags: #ChinaMarketAccess #LifeSciencesStrategy #PricingAndReimbursement #ChinaHealthPolicy #CommercialHealthInsurance
September 17, 2026
·
1 min read
Press Releases
Compass Pathways Launches ‘Change the Tune in TRD’ in the U.S. to Advance HCP Understanding of Treatment-Resistant Depression at Psych Congress 2026
September 15, 2026
·
6 min read
Press Releases
Ainnocence Shows AINN-P1 Protein Foundation Model Improves Antibody-Antigen Affinity Ranking by 28% - From Sequence Alone
Ainnocence’s foundation model trained from scratch, requiring no structure, no multiple sequence alignment, no fine-tuning, training in hours rather than weeks.
August 27, 2026
·
1 min read
Bio NC
Tune Therapeutics Presents First Data Supporting TUNE-401:a First-in-Class Epigenetic Silencer for Hepatitis B
Tune Therapeutics Presents First Data Supporting TUNE-401: a First-in-Class Epigenetic Silencer for Hepatitis B.
December 6, 2023
·
4 min read
Bio NC
Tune Therapeutics Reveals Epigenetic Editing Program Targeting Hepatitis B Virus
Pioneering epigenome editing company Tune Therapeutics has announced it is working on a new and potentially curative approach to treating chronic HBV infection.
November 13, 2023
·
3 min read
Press Releases
AASLD 2024: Tune Therapeutics Shows Near-Complete HepB Virus Repression with Tune-401 Epigenetic Silencer
November 20, 2024
·
3 min read
Press Releases
Seawolf Therapeutics Debuts With $100 Million to Advance DNA-Based Therapeutics
November 16, 2026
·
3 min read
1 of 30,105
Next